Skip to main content Accessibility help
×
Home

The mucopolysaccharidoses: a success of molecular medicine

  • Lorne A. Clarke (a1)

Abstract

The mucopolysaccharidoses represent a devastating group of lysosomal storage diseases affecting approximately 1 in 25 000 individuals. Advances in biochemistry and genetics over the past 25 years have resulted in the identification of the key hydrolases underlying the mucopolysaccharidoses, with subsequent isolation and characterisation of the genes involved. Ultimately these advances have led to the recent development of specific treatment regimens for some of the mucopolysaccharidoses, in the form of direct enzyme replacement. Direct replacement of the defective gene product has been attempted for very few genetic disorders, and thus the experience gained in the lysosomal storage diseases by the development, evaluation and integration of treatment regimens into healthcare is instructive for other rare genetic disorders. This review focuses on the pathophysiology of the mucopolysaccharidoses and highlights the complex biochemical and physiological perturbations that underlie the disease phenotype.

Copyright

References

Hide All
1Neufeld, E.S. and Muenzer, J. (2007) The mucopolysaccharidoses. In the Online Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R. et al. eds), Chapter 136, McGraw-Hill. http://genetics.accessmedicine.com/mmbid/public/
2McKusick, V.A. et al. (1965) The genetic mucopolysaccharidoses. Medicine 44, 445-483
3McKusick, V.A. (1966) Heritable Disorders of Connective Tissue, Mosby
4Roubicek, M., Gehler, J. and Spranger, J. (1985) The clinical spectrum of α-L-iduronidase deficiency. Am J Med Genet 20, 471-481
5Young, I.D. et al. (1982) A clinical and genetic study of Hunter's syndrome. 1. Heterogeneity. J Med Genet 6, 401-407
6Ashton, L.J. et al. (1992) Immunoquantification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Gene 50, 787-794
7Parkinson-Lawrence, E. et al. (2005) Analysis of normal and mutant iduronate-2-sulphatase conformation. Biochem J 386, 395-400
8Fuller, M. et al. (2005) Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 84, 18-24
9Beesley, C.E. et al. (2001) Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 109, 503-511
10Bunge, S. et al. (1995) Mucopolysaccharidosis type I: indentification of 13 novel mutations of the α-L-iduronidase gene. Hum Mutat 6, 91-94
11Terlato, N.J. and Cox, G.F. (2003) Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med 5, 286-294
12Brooks, D.A. et al. (2001) Glycosidase active site mutations in human alpha-L-iduronidase. Glycobiology 11, 741-750
13Timms, K.M. et al. (1997) Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet 6, 479-486
14Vafiadaki, E. et al. (1998) Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child 79, 237-241
15Froissart, R. et al. (2002) Mucopolysaccharidosis type II–genotype/phenotype aspects. Acta Paediatr Suppl 91, 82-87
16Karageorgos, L. et al. (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28, 897-903
17Litjens, T. et al. (1996) Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 58, 1127-1134
18Rempel, B.P., Clarke, L.A. and Withers, S.G. (2005) A homology model for human α-L-iduronidase: insights into human disease. Hum Mol Genet 85, 28-37
19Treacy, E., Childs, B. and Scriver, C.R. (1995) Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison. Am J Hum Genet 56, 359-367
20Walkley, S.U. and March, P.A. (1993) Biology of neuronal dysfunction in storage disorders. J Inher Metab Dis 16, 284-287
21Walkley, S.U. (2004) Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 15, 433-444
22Walkley, S.U., Zervas, M. and Wiseman, S. (2000) Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. Cereb Cortex 10, 1028-1037
23Walkley, S.U. et al. (2005) Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. Neuropathol Appl Neurobiol 31, 536-544
24Jolly, R.D. and Walkley, S.U. (1997) Lysosomal storage diseases of animals: an essay in comparative pathology. Vet Pathol 34, 527-548
25Turnbull, J., Powell, A. and Guimond, S. (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11, 75-82
26Bülow, H.E. and Hobert, O. (2006) The molecular diversity of glycosaminoglycans shapes animal development. Annu Rev Cell Dev Biol 22, 375-407
27Taylor, K.R. and Gallo, R.L. (2006) Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 20, 9-22
28Jackson, R.L., Busch, S.J. and Cardin, A.D. (1991) Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71, 481-539
29Prydz, K. and Dalen, K.T. (2000) Synthesis and sorting of proteoglycans. J Cell Sci 113, 193-205
30Bishop, J.R., Schuksz, M. and Esko, J.D. (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037
31Perrimon, N. and Bernfield, M. (2001) Cellular functions of proteoglycans-an overview. Semin Cell Dev Biol 12, 65-67
32Bernfield, M. et al. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777
33Yamaguchi, Y. (2001) Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin Cell Dev Biol 12, 99-106
34Handel, T.M. et al. (2005) Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu Rev Biochem 74, 385-410
35Wraith, J.E. et al. (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (Laronidase). J Pediatr 144, 581-588
36Muenzer, J. et al. (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8, 465-473
37Harmatz, P. et al. (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blinded, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on, open-label extension study. J Pediatr 148, 533-539
38Sands, M.S. et al. (1994) Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 93, 2324-2331
39Guffon, N. et al. (1998) Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 133, 119-125
40Peters, C. et al. (1996) Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87, 4894-4902
41Peters, C. et al. (1998) Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group Blood 91, 2601-2608
42Souillet, G. et al. (2003) Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transpl 31, 1105-1117
43Staba, S.L. et al. (2004) Cord-blood transplants from unrelated donors in patients with Hurler syndrome. N Eng J Med 350, 1960-1969
44Vellodi, A. et al. (1997) Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 76, 92-99
45Whitley, C.B. et al. (1993) Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 46, 209-218
46Guffon, N. et al. (2001) Outcome of bone marrow transplantation in eight patients with Hunter disease. J Inherit Metab Dis 24, 172
47Vellodi, A. et al. (1999), Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22, 638-648
48Sivakumur, P. and Wraith, J.E. (1999) Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 22, 849-850
49Grewal, S.S. et al. (2005) Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 7, 143-146
50Wraith, J.E. et al. (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human α-L-iduronidase (Laronidase). Pediatrics 120, e37-e46
51Beck, M. (2007) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121, 1-22
52Sands, M.S. and Davidson, B.L. (2006) Gene therapy for lysosomal storage diseases. Mol Ther. 13, 839-849
53Vogler, C. et al. (2001) Murine mucopolysaccharidosis VII: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease. Pediatr Dev Pathol. 4, 421–33
54Li, H.H. et al. (1999) Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding α-N-acetylglucosaminidase. Proc Natl Acad Sci U S A 96, 14505-14510
55Vogler, C. et al. (2005) Early onset of lysosomal storage disease in murine model of mucopolysaccharidosis type VII: undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Devel Pathol 8, 453-462
56Bhaumik, M. et al. (1999) A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9, 1389-1396
57Russell, C. et al. (1998) Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 53, 349–61
58Nuttall, J.D. et al. (1999) Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif Tissue Int 65, 47-52
59McGlynn, R., Dobrenis, K. and Walkley, S.U. (2004) Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 480, 415-426
60Tomatsu, S. et al. (2005) Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 28, 743-757
61Ramsay, S.L. et al. (2004) Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionization tandem spectrometry: in utero indicators of lysosomal storage diseases. Mol Genet Metab 83, 231-238
62Greenwood, R.S. et al. (1978) Sanfilippo A syndrome in the fetus. Clin Genet 13, 241-250
63Wiesmann, U.N. et al. (1980) Neonatal mucopolysaccharidosis II (Hunter): a pathogenetic study. Pediatr Res 14, 749-756
64Casal, M.L. and Wolfe, J.H. (2000) Mucopolysaccharidosis type VII in the developing mouse fetus. Pediatr Res 47, 750-756
65Jones, M.Z. et al. (2004) Caprine mucopolysaccharidosis IIID. J Mol Neurosci 24, 277-291
66Clarke, L.A. et al. (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet. 6, 503-511
67Beutler, E. (2006) Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 88 208-215
68Van Hoof, F. and Hers, H.G. (1968) Eur J Biochem 7, 34-44
69Sands, M.S. et al. (1994) Enzyme replacement therapy for murine mucopolysaccharidosis type VII.J. Clin. Invest. 93, 2324-2331
70Avila, J.L. and Convit, J. (1975) Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J 152, 57-64
71Canstantopoulous, G. and Dekaban, A.S. (1978) Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four type of mucopolysaccharidosis and in normal controls. J Neurochem 30, 965-973
72Jones, M.Z. et al. (1997) Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics. J Neuropathol Exp Neurol 56, 1158-1167
73Jones, M.Z. et al. (1998) Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics. J Neuropathol Exp Neurol 57, 148-157
74Liour, S.S. et al. (2001) Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID. Mol Genet Metab 72, 239-247
75Walkley, S.U. (2004) Pathologic cascades and brain dysfunction. In Lysosomal Disorders of the Brain. (Platt, F.M. and Walkley, S.U., eds), pp 290-324, Oxford
76Walkley, S.U. and Suzuki, K. (2004) Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochem Biophys Acta 1685, 48-62
77Pagano, R.E. et al. (2000) Membrane traffic in sphingolipid diseases. Traffic 1, 807-815
78Jeyakumar, M. et al. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126, 974-987
79Myerowitz, R. et al. (2002) Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet 11, 1343-1350
80Langmade, S.J. et al. (2006) Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann–Pick C disease. Proc Natl Acad Sci U S A 103, 13807-13812
81Settembre, C. et al. (2007) Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc Natl Acad Sci U S A 104, 4506-4511
82Ohmi, K. et al. (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A 100, 1902-1907
83Jeyakumar, M. et al. (2004) NSAIDs increase survival in the sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56, 642-649
84Ko, D. et al. (2005), Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet 1, 81-95
85Simonaro, C.M., Haskins, M.E. and Schuchman, E.H. (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 81, 1319-1328
86Simonaro, C.M. et al. (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57, 701-707
87Mulloy, B. and Rider, C.C. (2006) Cytokines and proteoglycans: an introductory overview. Biochem Soc T 34, 409-413
88Parish, C.R. (2006) The role of heparin sulphate in inflammation. Nat Rev Immunol 6, 633-643
89Randall, D.R. et al. (2006) Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab 88, 235-243
90Maekawa, H., Sato, H. and Tollefsen, D.M. (2000) Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex. Thromb Res 100, 443-451
91Verhamme, I.M., Bock, P.E. and Jackson, C.M. (2004) The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J Biol Chem 279, 9785-9795
92Pike, R.N. et al. (2005) Control of the coagulation system by serpins getting by with a little help from glycosaminoglycans. FEBS J 272, 4842-4851
93Meins, M. et al. (2001) Progressive neuronal and motor dysfunction in mice overexpressing the serine protease inhibitor protease nexin-1 in postmitotic neurons. J Neurosci 21, 8830-8841
94Ginsberg, S.D. et al. (1999) Accumulation of intracellular amyloid-beta peptide (A beta 1–40) in mucopolysaccharidosis brains. J Neuropathol Exp Neurol 58, 815-824
95Watanabe, N. et al. (2004) Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease. FASEB J 18, 1013-1015
96Mayer-Sonnenfeld, T. et al. (2005) The metabolism of glycosaminoglycans is impaired in prion diseases. Neurobiol Dis 20, 738-743
97Ryazantsev, S. et al. (2007) Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B. Mol Genet Metab 90, 393-401
98Hinek, A. and Wilson, S.E. (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Path 156, 925-938
99Kozel, B.A., Ciliberto, C.H. and Mecham, R.P. (2004) Deposition of tropoelastin into the extracellular matrix requires a competent elastic fiber scaffold but not live cells. Matrix Biol 23, 23-34
100Hinek, A. et al. (2004) Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am J Pathol 164, 119-131
101Li, Z. et al. (2004) Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 279, 5470-5479
102Selent, J. et al. (2007) Selective inhibition of the collagenase activity of cathepsin K. J Biol Chem 282, 16492-16501
103Jackson, R.A., Nurcombe, V. and Cool, S.M. (2006) Coordinated fibroblast growth factor and heparin sulfate regulation of osteogenesis. Gene 379, 79-91
104Shinmyouzu, K. et al. (2007) Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand. Biochem Biophys Res Commun 354, 447-452
105Rauch, U. and Kappler, J. (2006) Chondroitin/Dermatan sulfates in the central nervous system: their structures and functions in health and disease. Adv Pharmacol. 53, 337-356
106Huntington, J.A. (2003) Mechanisms of glycosaminoglycan activation of the serpins inhemostasis. J Thromb Haemost 1, 1535-1549
107Roughley, P.J. (2006) The structure and function of cartilage proteoglycans. Eur Cell Mater 12, 92-101
108Chang, X., Yamada, R. and Yamamoto, K. (2005) Inhibition of antithrombin by hyaluronic acid may be involved in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 7, R268-R273
109Knox, S.M. and Whitelock, J.M. (2006) Perlecan: how does one molecule do so many things? Cell Mol Life Sci 63, 2435-2445
110Gomes, R.R. Jr, Farach-Carson, M.C. and Carson, D.D. (2004) Perlecan functions in chondrogenesis: insights from in vitro and in vivo models. Cells Tissues Organs 176, 79-86
111Gautam, M. et al. (1996) Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85, 525–35
112Marneros, A.G. and Olsen, B.R. (2005) Physiological role of collagen XVIII and endostatin. FASEB J 19, 716-728
113Watanabe, H., Yamada, Y. and Kimata, K. (1998) Roles of aggrecan, a large chondroitin sulfate proteoglycan, in cartilage structure and function. J Biochem 124, 687-693
114Yoon, J.H. and Halper, J. (2004) Tendon proteoglycans: biochemistry and function. J Musculoskelet Neuronal Interact 5, 22-34
115Yamaguchi, Y. (2001) Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin Cell Dev Biol 12, 99-106
116Bovolenta, P. and Fernaud-Espinosab, I. (2000) Nervous system proteoglycans as modulators of neurite outgrowth. Prog Neurobiol 61, 113-132
117Knudson, C.B. and Knudson, W. (2001) Cartilage proteoglycans. Semin Cell Dev Biol 12, 69-78
118Chakravarti, S. (2006) Focus on molecules: keratocan (KERA). Exp Eye Res 82, 183-184
119Kakkis, E.D. et al. (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344, 182-188
120Sifuentes, M. et al. (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90, 171-180
121Muenzer, J. et al. (2007) A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 90, 329-337
122Harmatz, P. (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144, 574-580
123Harmatz, P. (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681-e689
Walkley, S.U. (2007) Pathogenic mechanisms in lysosomal disease: a reappraisal of the role of the lysosome. Acta Paediatr Suppl 96, 26-32
Ponder, K.P. and Haskins, M.E. (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7, 1333-1345
Sillence, D.J. (2007) New insights into glycosphingolipid functions—storage, lipid rafts, and translocators. Int Rev Cytol 262, 151-189
Simons, K. and Gruenberg, J. (2000) Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol 10, 459-462

Key patient support group websites:

http://www.goldinfo.org: (Global Organisation for Lysosomal Diseases)
http://www.lysosomaldiseasenetwork.org (Lysosomal Disease Network)
http://www.rarediseases.org (National Organization for Rare Diseases)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed